Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SHEN26 Capsule in Healthy Participants

NCT05504746 is registered in ClinicalTrials.gov with Shenzhen Kexing Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05504746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05504746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SHEN26 Capsule in Healthy Participants
Lead sponsor
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 8, 2022
Completion date
December 11, 2022
Enrollment
86 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants